Welcome to our dedicated page for Cardinal Health news (Ticker: CAH), a resource for investors and traders seeking the latest updates and insights on Cardinal Health stock.
Cardinal Health, Inc. distributes pharmaceuticals and specialty products and manufactures and distributes medical, laboratory, home-health and direct-to-patient products and services. The company also operates nuclear pharmacies and manufacturing facilities and provides performance and data solutions for healthcare customers.
Recurring company updates cover financial results and fiscal outlooks, dividend actions, share repurchases, debt activity, segment performance in Global Medical Products and Distribution, at-Home Solutions, Nuclear and Precision Health Solutions and OptiFreight Logistics. Other developments include biosimilars and advanced-therapy research reports, Actinium-225 production capacity for radiopharmaceutical applications, and board governance changes.
Cardinal Health (NYSE: CAH) has announced it will release its third-quarter financial results for fiscal year 2025 on May 1, 2025, before the New York Stock Exchange opens. The company will host a webcast discussion of the results at 8:30 a.m. Eastern.
Investors can access the webcast and accompanying slide presentation through Cardinal Health's Investor Relations page without requiring an access code. The presentation materials and webcast replay will remain available on the company's Investor Relations page for 12 months following the event.
Cardinal Health (NYSE:CAH) has announced two significant additions to its Board of Directors, effective March 7, 2025. Robert Musslewhite, former CEO of Definitive Healthcare Corp., and Sudhakar Ramakrishna, current President and CEO of SolarWinds , have been elected as independent directors.
Musslewhite, with over 20 years of leadership experience, brings expertise in healthcare analytics and technology. He will serve on the board's Audit and Human Resources and Compensation Committees. Ramakrishna, a global technology leader with extensive cybersecurity experience, will join the Audit and Risk Oversight Committees.
Both appointments strengthen Cardinal Health's technological capabilities and strategic oversight. Musslewhite's background includes CEO roles at OptumInsight and The Advisory Board Company, while Ramakrishna's experience spans leadership positions at companies including Pulse Secure, Citrix Systems, and Polycom.
Cardinal Health (NYSE: CAH) has announced that its Board of Directors has approved a quarterly dividend payment. The company will distribute $0.5056 per share from its capital surplus. Shareholders who are recorded as owners at the close of business on April 1, 2025, will receive the dividend payment on April 15, 2025.
Cardinal Health (CAH) reported Q2 FY25 revenues of $55.3 billion, a 4% decrease from Q2 FY24, though revenue increased 16% excluding a large customer contract expiration. GAAP operating earnings rose 9% to $549 million, with GAAP diluted EPS at $1.65. Non-GAAP operating earnings grew 9% to $635 million, driven by Pharmaceutical and Specialty Solutions segment.
The company raised its FY25 non-GAAP EPS guidance to $7.85-$8.00 from $7.75-$7.90. Notable developments include completing acquisitions of 73% ownership in GI Alliance and Integrated Oncology Network. Pharmaceutical segment profit increased 7% to $531 million, while Global Medical Products segment profit rose to $18 million.
Cardinal Health (NYSE: CAH) announced the construction of a new 340,000 square foot distribution center in Fort Worth, Texas, supporting its at-Home Solutions business. The facility will consolidate two existing warehouses, adding 74,000 square feet of inventory capacity while retaining current workforce. The center will ship approximately 10,000 packages daily to patients nationwide.
The facility will feature advanced technology including 74 robots, a 1,500-foot automated conveyor system, and four automated box-making machines producing 500 custom boxes hourly. It will utilize a cloud-based warehouse management system with AI capabilities for inventory management. The company reported its best-ever metrics in quality, service, efficiency, and employee safety in Q1 FY2025. The facility is expected to be fully operational by Summer 2025.
Cardinal Health (NYSE: CAH) has announced it will release its second-quarter financial results for fiscal year 2025 on January 30, before the New York Stock Exchange opens. The company will host a webcast discussion of the results starting at 8:30 a.m. Eastern. Investors can access the webcast and accompanying slide presentation through Cardinal Health's Investor Relations page without requiring an access code. The presentation materials and webcast replay will remain available on the company's Investor Relations page for 12 months.
Cardinal Health (NYSE: CAH) announced the U.S. launch of its Kendall SCD SmartFlow™ Compression System, an advanced solution for preventing deep vein thrombosis and pulmonary embolism. The system features Vascular Refill Detection technology that customizes compression cycles to match patient's unique vascular refill time, increasing blood flow efficiency. Notable features include Patient Sensing™ Technology that automatically detects therapy application and alerts for incorrect usage. The system will be available internationally in early 2025.
Cardinal Health (NYSE: CAH) has entered into a definitive agreement to acquire Advanced Diabetes Supply Group (ADSG), a national distributor of diabetes-related Durable Medical Equipment. ADSG, headquartered in Carlsbad, CA, serves approximately 500,000 patients through home delivery of diabetes products, including continuous glucose monitoring devices and testing supplies. The company will join Cardinal Health's at-Home Solutions business, which currently serves over 5 million patients annually. The acquisition is pending customary closing conditions and regulatory approvals.
Cardinal Health (NYSE: CAH) announced two strategic acquisitions: a 71% stake in GI Alliance (GIA) for $2.8 billion and Advanced Diabetes Supply Group (ADSG) for $1.1 billion. GIA, the leading gastroenterology management services organization with over 900 physicians across 345 locations, will operate within Cardinal's Pharmaceutical and Specialty Solutions segment. ADSG, serving approximately 500,000 diabetes patients annually, will merge with Cardinal's at-Home Solutions business. Both acquisitions are expected to close in early 2025 and be accretive to revenue, segment profit growth, and non-GAAP EPS in the first 12 months post-closing.
Cardinal Health (NYSE: CAH) has announced that its Board of Directors has approved a quarterly dividend of $0.5056 per share from the company's capital surplus. The dividend will be paid on January 15, 2025, to shareholders who are on record as of January 2, 2025.